Subsequent Neoplasm Risk after Modern Mediastinal Radiotherapy for Pediatric Hodgkin Lymphoma: Insights from a Multi-Institutional Children’s Oncology Group Trial
The study reports a significant increase in neoplasms, with 20% of patients affected within 15 years post-treatment.
Multi-institutional trial findings highlight the association between radiotherapy and subsequent neoplasms in survivors.
This study emphasizes potential long-term health risks for pediatric patients, calling for ongoing surveillance post-treatment.
Like
Bookmark
Share
Like
Bookmark
Share
Subsequent Neoplasm Risk after Modern Mediastinal Radiotherapy for Pediatric Hodgkin Lymphoma: Insights from a Multi-Institutional Children’s Oncology Group Trial | Synapse